Suvretta Capital Management 13F holdings, Q3 2023
Holdings as of September 30, 2023 · filings on SEC EDGAR · latest filing →
Suvretta Capital Management disclosed 87 US equity positions worth $1.9bn in its Q3 2023 13F filing. The largest position was RPRX at 6.0% of the reported book, followed by BHVN and ARCELLX INC. Against the Q2 2023 filing, it opened 7 new positions, added to 28 and reduced 7 among the top 50 holdings.
What did Suvretta Capital Management own in Q3 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2023 |
|---|---|---|---|---|---|---|---|
| 1 | RPRX ROYALTY PHARMA PLC | Healthcare | 6.0% | $111.2m | 4,095,745 | 34% | added |
| 2 | BHVN BIOHAVEN LTD | Healthcare | 5.6% | $104.2m | 4,005,600 | 4% | added |
| 3 | ARCELLX INC | 5.6% | $103.0m | 2,869,967 | 1% | added | |
| 4 | HORIZON THERAPEUTICS PUB L | 4.9% | $91.0m | 786,313 | -1% | reduced | |
| 5 | INSM INSMED INC | Healthcare | 4.7% | $87.0m | 3,446,334 | 11% | added |
| 6 | META META PLATFORMS INC | Communication Services | 4.6% | $84.3m | 280,645 | 12% | added |
| 7 | AMZN AMAZON COM INC | Consumer Cyclical | 4.3% | $78.7m | 619,469 | 89% | added |
| 8 | AMD ADVANCED MICRO DEVICES INC | Technology | 3.9% | $71.6m | 696,510 | 88% | added |
| 9 | INTRA-CELLULAR THERAPIES INC | 3.9% | $71.4m | 1,369,849 | 14% | added | |
| 10 | MSFT MICROSOFT CORP | Technology | 3.7% | $68.9m | 218,170 | – | new |
| 11 | KURA KURA ONCOLOGY INC | Healthcare | 3.6% | $66.9m | 7,335,845 | 4% | added |
| 12 | WYNN WYNN RESORTS LTD | Consumer Cyclical | 2.3% | $42.5m | 460,048 | 54% | added |
| 13 | MARINUS PHARMACEUTICALS INC | 2.3% | $41.9m | 5,204,942 | 28% | added | |
| 14 | 89BIO INC | 2.2% | $41.6m | 2,694,404 | 13% | added | |
| 15 | GE GENERAL ELECTRIC CO | Industrials | 2.1% | $38.8m | 350,969 | 82% | added |
| 16 | NVDA NVIDIA CORPORATION | Technology | 2.1% | $38.5m | 88,548 | 14% | added |
| 17 | CMG CHIPOTLE MEXICAN GRILL INC | Consumer Cyclical | 2.0% | $37.4m | 20,400 | – | new |
| 18 | GPN GLOBAL PMTS INC | Industrials | 1.8% | $32.8m | 284,488 | 1% | added |
| 19 | 430 TERNS PHARMACEUTICALS INC | 1.6% | $30.4m | 6,041,910 | 9% | added | |
| 20 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.6% | $29.8m | 3,053,300 | 38% | added |
| 21 | LVS LAS VEGAS SANDS CORP | Consumer Cyclical | 1.6% | $29.5m | 642,833 | -6% | reduced |
| 22 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 1.5% | $27.9m | 3,492,147 | 2% | added |
| 23 | ORCL ORACLE CORP | Technology | 1.5% | $27.0m | 255,311 | -20% | reduced |
| 24 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.4% | $25.4m | 5,718,881 | 0% | held |
| 25 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.3% | $24.2m | 679,459 | 25% | added |
| 26 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.3% | $23.3m | 2,420,851 | 19% | added | |
| 27 | RH RH | Consumer Cyclical | 1.2% | $21.4m | 80,989 | -3% | reduced |
| 28 | LLY ELI LILLY & CO | Healthcare | 1.1% | $21.0m | 39,100 | – | new |
| 29 | STRO SUTRO BIOPHARMA INC | Healthcare | 1.1% | $20.4m | 5,883,693 | 0% | held |
| 30 | BCYC BICYCLE THERAPEUTICS PLC | Healthcare | 1.1% | $20.3m | 1,010,976 | – | new |
| 31 | ZURA ZURA BIO LTD | Healthcare | 1.0% | $18.8m | 2,850,000 | 0% | held |
| 32 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.0% | $18.7m | 353,741 | 1839% | added |
| 33 | PROK PROKIDNEY CORP | 1.0% | $17.7m | 3,867,843 | 21% | added | |
| 34 | COF CAPITAL ONE FINL CORP | Financial Services | 1.0% | $17.6m | 181,660 | -9% | reduced |
| 35 | WFC WELLS FARGO CO NEW | Financial Services | 0.9% | $17.5m | 428,506 | 1% | added |
| 36 | APO APOLLO GLOBAL MGMT INC | Financial Services | 0.9% | $17.2m | 191,900 | – | new |
| 37 | HLT HILTON WORLDWIDE HLDGS INC | Consumer Cyclical | 0.9% | $17.1m | 113,962 | -1% | reduced |
| 38 | INFLARX NV | 0.9% | $17.1m | 5,733,910 | 0% | held | |
| 39 | MCK MCKESSON CORP | Healthcare | 0.9% | $16.3m | 37,540 | 1951% | added |
| 40 | JNJ JOHNSON & JOHNSON | Healthcare | 0.8% | $14.0m | 90,097 | 9% | added |
| 41 | UNH UNITEDHEALTH GROUP INC | Healthcare | 0.7% | $13.7m | 27,223 | 112% | added |
| 42 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.6% | $11.5m | 2,963,704 | 40% | added |
| 43 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.6% | $11.2m | 454,000 | 0% | held |
| 44 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.6% | $10.7m | 597,099 | – | new |
| 45 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.5% | $9.5m | 7,364,438 | 0% | held |
| 46 | ANAB ANAPTYSBIO INC | Healthcare | 0.5% | $8.6m | 479,445 | – | new |
| 47 | KEZAR LIFE SCIENCES INC | 0.5% | $8.5m | 7,167,591 | 0% | held | |
| 48 | ALVOTECH | 0.5% | $8.5m | 928,402 | -7% | reduced | |
| 49 | SNY SANOFI | 0.3% | $6.2m | 116,041 | 0% | held | |
| 50 | ELAN ELANCO ANIMAL HEALTH INC | Healthcare | 0.3% | $6.0m | 536,500 | 23% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.